We performed bulk TCRβ sequencing on sorted CD4+ and CD8+ TILs from bilateral AB1-HA tumors treated with anti-CTLA-4 and anti-OX-40 ICT because we previously observed robust anti-tumor effects with this combination (Figure 2(a,b)).22 Bilateral tumors were harvested when sizes between ICT and control groups were similar for both flanks (Figure 2(b), Supp Figure S3A). Here, CTLA4 is linked to neoplasm.